ArticleThe New England journal of medicine2024
Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis.
Abstract readLetter
In one paragraph
Article in The New England journal of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Guideline
- Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 update.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Guideline
- Provider Perspectives on the Delivery of Long-Acting PrEP for HIV Prevention to Men Who Have Sex with Men and Who Use Methamphetamine.AIDS patient care and STDs · 2026Article
- Rapid, low-cost, and portable molecular detection of HIV-1 subtype B and HCV 1a directly from blood.Microbiology spectrum · 2026Article
- A Narrative Review of Remote Biospecimen Collection Product and Implementation Considerations for Sexual Health Clinical Research.AIDS and behavior · 2026Review
- Prospective HIV RNA screening with long-acting cabotegravir pre-exposure prophylaxis in HPTN 083.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Estimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083.The Journal of infectious diseases · 2026Article
- HIV low-level viraemia: considerations for prevention and treatment in an era of highly effective and durable antiretroviral therapy regimens.Journal of the International AIDS Society · 2026Article
- Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies.The Journal of infectious diseases · 2026Article
- Top 10 Questions and Answers From the National Clinician Consultation Center: What is Coming Up for Clinicians Across the United States.Topics in antiviral medicine · 2025Article
- HIV-1 testing in the context of expanding PrEP modalities.Journal of the International AIDS Society · 2025Article
- Early Virologic Success on Antiretroviral Therapy Among Individuals With Breakthrough HIV Acquisition on Long-Acting Cabotegravir Pre-exposure Prophylaxis.Open forum infectious diseases · 2025Article
- Review
- HIV diagnosis during acute infection: implications of long-acting preexposure prophylaxis and other evolving challenges.Current opinion in HIV and AIDS · 2025Review
- Preventing HIV in women in Africa.Nature medicine · 2025Review
- HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084.AIDS research and human retroviruses · 2025Article
- Southern African HIV Clinicians Society guideline on pre-exposure prophylaxis to prevent HIV.Southern African journal of HIV medicine · 2025Article
- Nucleic acid amplification testing using dried blood spots to confirm the diagnosis of HIV-1 in adults.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2024Article
- Integrating harm reduction and addiction care in HIV prevention among persons who inject drugs in the United States-a narrative review.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Raphael J LandovitzUniversity of California, Los Angeles, Los Angeles, CA rlandovitz@mednet.ucla.edu.
Sinead Delany-MoretlweUniversity of the Witwatersrand, Johannesburg, South Africa.
Jessica M FogelJohns Hopkins University, Baltimore, MD.
Mark A MarzinkeJohns Hopkins University, Baltimore, MD.
Estelle Piwowar-ManningJohns Hopkins University, Baltimore, MD.
Paul RichardsonJohns Hopkins University, Baltimore, MD.
Elias K HalvasUniversity of Pittsburgh, Pittsburgh, PA.
John W MellorsUniversity of Pittsburgh, Pittsburgh, PA.
Deborah PersaudJohns Hopkins University, Baltimore, MD.
Ryan KofronUniversity of California, Los Angeles, Los Angeles, CA.
Marybeth McCauleyFHI 360, Durham, NC.
Scott RoseFHI 360, Durham, NC.
Alex R RinehartViiV Healthcare, Research Triangle Park, NC.
James F RooneyGilead Sciences, Foster City, CA.
Adeola AdeyeyeNational Institutes of Health, Bethesda, MD.
Myron S CohenUniversity of North Carolina at Chapel Hill, Chapel Hill, NC.
Deborah DonnellFred Hutchinson Cancer Center, Seattle, WA.
Mina C HosseinipourUniversity of North Carolina at Chapel Hill, Chapel Hill, NC.
Beatriz GrinsztejnInstituto de Pesquisa Clinica Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil.
Susan H EshlemanJohns Hopkins University, Baltimore, MD.
HPTN 083 and 084 Study Teams
Funding
LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI MYRON Scott COHEN, Sinead Delany-Moretlwe · 2011 to 2026
$779.5MSDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9MLC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2MHIV Prevention trials Network (HPTN) Coordinating and Operations CenterU01AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI VERMUND, STEN H. · 2006 to 2010
$72.7MUCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8MWits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8MUnits for HIV/AIDS Clinical Trials NetworksU01AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI SANNE, IAN MATTHIAS · 2007 to 2011
$24.2MNIAID NIH HHS U01 AI068619NIAID NIH HHS U01 AI069463NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069463
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.